Sarissa Capital Management as of June 30, 2015
Portfolio Holdings for Sarissa Capital Management
Sarissa Capital Management holds 16 positions in its portfolio as reported in the June 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ariad Pharmaceuticals | 24.4 | $106M | 13M | 8.27 | |
| Abbvie (ABBV) | 24.4 | $106M | 1.6M | 67.19 | |
| Quest Diagnostics Incorporated (DGX) | 9.6 | $42M | 575k | 72.52 | |
| Medicines Company | 9.0 | $39M | 1.4M | 28.61 | |
| Aegerion Pharmaceuticals | 8.9 | $39M | 2.0M | 18.97 | |
| Amgen (AMGN) | 7.1 | $31M | 200k | 153.52 | |
| Merck & Co (MRK) | 5.2 | $23M | 400k | 56.93 | |
| Intra Cellular Therapies (ITCI) | 2.6 | $12M | 360k | 31.95 | |
| Apricus Bioscience | 2.6 | $11M | 6.5M | 1.71 | |
| Repros Therapeutics | 1.9 | $8.1M | 1.1M | 7.15 | |
| Vivus | 1.4 | $6.1M | 2.6M | 2.36 | |
| Kindred Biosciences | 1.1 | $4.7M | 689k | 6.82 | |
| AVEO Pharmaceuticals | 0.9 | $4.0M | 2.3M | 1.74 | |
| Biosante Pharmaceuticals (ANIP) | 0.4 | $1.9M | 31k | 62.06 | |
| Targacept | 0.4 | $1.8M | 630k | 2.79 | |
| Eleven Biotherapeutics | 0.0 | $116k | 41k | 2.82 |
